A potential drug against acute myeloid leukemia shows antitumor effect

Hematology and Hemotherapy
–

‘Nature’

In a phase I trial, the menin inhibitor revumenib achieves a complete response in 18 patients with AML, revealing a cause of resistance to this potential new treatment.

Acute myeloid leukemia. Image: ATLAS OF HAEMATOLOGICAL CYTOLOGY.